TY  - JOUR
A1  - Einsele, Hermann
A1  - Borghaei, Hossein
A1  - Orlowski, Robert Z.
A1  - Subklewe, Marion
A1  - Roboz, Gail J.
A1  - Zugmaier, Gerhard
A1  - Kufer, Peter
A1  - Iskander, Karim
A1  - Kantarjian, Hagop M.
T1  - The BiTE (Bispecific T‐Cell Engager) Platform: Development and Future Potential of a Targeted Immuno‐Oncology Therapy Across Tumor Types
JF  - Cancer
N2  - Immuno‐oncology therapies engage the immune system to treat cancer. BiTE (bispecific T‐cell engager) technology is a targeted immuno‐oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor‐specific antigens, allowing off‐the‐shelf immuno‐oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B‐cell non‐Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small‐cell lung cancer). BiTE molecules with an extended half‐life relative to the canonical BiTE molecules are also being developed. Advances in immuno‐oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments.
KW  - B cell
KW  - blinatumomab
KW  - hematologic malignancies
KW  - T cell
KW  - tumor‐specific antigen
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-215426
VL  - 126
IS  - 14
SP  - 3192
EP  - 3201
ER  -